John Petrovich will be the CEO of Calando Pharmaceuticals, a new subsidiary of Arrowhead Research that will focus on commercializing therapeutic RNAi delivery technologies.
Other co-founders of Calando include Mark Davis, a professor of chemical engineering at the California Institute of Technology; John Rossi, a molecular geneticist at the City of Hope’s Beckman Research Institute; and Matt Vincent, a partner at the law firm Ropes & Gray.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
